Eli Lilly and Company Archives - Page 2 of 3 - PeptideBlog

Eli Lilly and Company

Eli Lilly and Company

29 registered trials on this site, 10 active. This page lists the trials this organization is registered as lead sponsor of, for the compounds covered on PeptideBlog.net. It is a registry listing, not an assessment of the company or its products.

Compounds covered

Registered trials

TrialCompoundPhaseStatusSponsorEnrolledPrimary completionRegistry updated
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432
EloralintidePhase 3Not yet recruitingEli Lilly and Company2,115Oct 2029Nov 17, 2026
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633
None linkedPhase 3Not yet recruitingEli Lilly and Company3,000Nov 2029Nov 17, 2026
A Study Assessing Eloralintide (LY3841136) in Healthy Participants
NCT07935304
EloralintidePhase 1Not yet recruitingEli Lilly and Company90Apr 2027Nov 13, 2026
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05936151
RetatrutidePhase 2CompletedEli Lilly and Company146Oct 1, 2025Nov 9, 2026
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475
NisotirostidePhase 2RecruitingEli Lilly and Company200May 2027Nov 4, 2026
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT07881458
EloralintidePhase 3RecruitingEli Lilly and Company1,000Oct 2029Nov 4, 2026
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953
BrenipatidePhase 3RecruitingEli Lilly and Company1,100Apr 2028Nov 4, 2026
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756
BrenipatidePhase 3RecruitingEli Lilly and Company1,000Feb 2028Nov 4, 2026
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
NCT07890376
LY4086940Phase 2Not yet recruitingEli Lilly and Company460Jan 2028Nov 3, 2026
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
NCT07808060
EloralintidePhase 1RecruitingEli Lilly and Company34Jun 2027Oct 8, 2026
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966
BrenipatidePhase 3RecruitingEli Lilly and Company1,100Apr 2028Oct 7, 2026
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
NCT06606106
BrenipatidePhase 1Active not recruitingEli Lilly and Company302Nov 2026Sep 30, 2026
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571
EloralintidePhase 2CompletedEli Lilly and Company367Jul 1, 2026Sep 29, 2026
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722
RetatrutidePhase 3Active not recruitingEli Lilly and Company1,250Aug 27, 2026Sep 28, 2026
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045
OrforglipronPhase 3CompletedEli Lilly and Company712Jul 21, 2026Sep 14, 2026
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066
RetatrutidePhase 3CompletedEli Lilly and Company2,335Apr 6, 2026Aug 21, 2026
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
NCT06945419
LY4086940Phase 1CompletedEli Lilly and Company219Aug 5, 2026Aug 19, 2026
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079
RetatrutidePhase 3CompletedEli Lilly and Company1,152Jun 16, 2026Jul 30, 2026
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
NCT05616013
BimagrumabPhase 2CompletedEli Lilly and Company507May 16, 2024Jul 8, 2026
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06230523
EloralintidePhase 2CompletedEli Lilly and Company263May 30, 2025Jun 24, 2026
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415
RetatrutidePhase 3Active not recruitingEli Lilly and Company600Oct 2028Jun 9, 2026
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728
BimagrumabPhase 2Active not recruitingEli Lilly and Company252Jan 16, 2026May 26, 2026
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
NCT06354660
RetatrutidePhase 3CompletedEli Lilly and Company537Jan 22, 2026Mar 5, 2026
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367
RetatrutidePhase 3CompletedEli Lilly and Company445Nov 14, 2025Jan 21, 2026
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
NCT06901349
BimagrumabPhase 2WithdrawnEli Lilly and Company–Jun 10, 2025Sep 24, 2025
A Study of LY3841136 in Healthy and Overweight Participants
NCT05295940
EloralintidePhase 1CompletedEli Lilly and Company148Jan 25, 2024Apr 1, 2024
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
NCT04881760
RetatrutidePhase 2CompletedEli Lilly and Company338May 16, 2022Sep 13, 2023
A Study of LY3457263 in Obese Participants
NCT05582096
NisotirostidePhase 1CompletedEli Lilly and Company38Jun 8, 2023Jul 18, 2023
A Study of LY3437943 in Participants With Type 2 Diabetes
NCT04867785
RetatrutidePhase 2CompletedEli Lilly and Company281Jul 8, 2022Jul 3, 2023

Data: ClinicalTrials.gov, U.S. National Library of Medicine. See the full trial tracker.